78269-85-9

Basic information

• Product Name: 1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&
• Synonyms: 1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&;N-[2-(Trimethylsilyl)ethoxycarbonyloxy]succinimide;Teoc-OSu;(TriMethylsilyl)ethoxycarbonyloxy]succiniMide;2,5-Dioxopyrrolidin-1-yl (2-(trimethylsilyl)-ethyl) carbonate;1-[[[2-(Trimethylsilyl)ethoxy]carbonyl]oxy]-2,5-pyrrolidinedione;Carbonic acid,2,5-dioxo-1-pyrrolidinyl [2-(triMethylsilyl)ethyl] ester;(triMethylsilyl)ethoxy]carbonyl}oxy)pyrrolidine-2,5-dione
• CAS NO: 78269-85-9
• Molecular Formula: C₁₀H₁₇NO₅Si
• Molecular Weight: 259.33
• Product Categories: Building Blocks;Heterocyclic Building Blocks;Pyrrolidines
• Mol File: 78269-85-9.mol

Chemical Properties

• Melting Point: 83-88 °C(lit.)
• Boiling Point: 308.6°C at 760 mmHg
• Flash Point: 140.4°C
• Appearance: /
• Density: 1.17g/cm³
• Vapor Pressure: 0.000675mmHg at 25°C
• Refractive Index: 1.479
• Storage Temp.: 2-8°C
• Solubility: soluble in Methanol
• CAS DataBase Reference: 1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&(CAS DataBase Reference)
• NIST Chemistry Reference: 1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&(78269-85-9)
• EPA Substance Registry System: 1-(2-(TRIMETHYLSILYL)ETHOXYCARBONYLOXY)&(78269-85-9)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26-36
• WGK Germany: 3
• Hazardous Substances Data: 78269-85-9(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Teoc-OSu is used as an acylating reagent for the synthesis of Teoc-amino acid derivatives, which are essential in the development of various pharmaceutical compounds. The reagent's ability to form stable derivatives with amino acids makes it a valuable tool in drug discovery and medicinal chemistry.
Used in Chemical Research:
In the field of chemical research, Teoc-OSu is utilized for the preparation of various organic compounds and materials. Its unique silicon-based structure allows for the exploration of new chemical reactions and the synthesis of novel molecules with potential applications in various industries.
Used in Material Science:
Teoc-OSu's silicon-based structure also makes it a candidate for use in material science, where it can be employed in the development of new materials with specific properties. These materials could have applications in electronics, coatings, or other advanced technologies.

InChI:InChI=1/C10H17NO5Si/c1-17(2,3)7-6-15-10(14)16-11-8(12)4-5-9(11)13/h4-7H2,1-3H3

Upstream product

• 2916-68-9 2-(Trimethylsilyl)ethanol 
• 32315-10-9 bis(trichloromethyl) carbonate 
• 74124-79-1 di(succinimido) carbonate 
• 6066-82-6 1-hydroxy-pyrrolidine-2,5-dione 
• 20160-60-5 2-(trimethylsilyl)-ethoxycarbonyl chloride 

Downstream Products

• 100821-66-7 Tmseoc-Phe-OH 
• 884513-98-8 C₃₃H₅₆ClN₃O₅Si 
• 1398570-17-6 Ethyl trans-4-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)cyclohexanecarboxylate 
• 1398570-18-7 Trans-4-({[2-(trimethylsilyl)ethoxy]carbonyl}amino)cyclohexanecarboxylic acid 
• 75-98-9 Trimethylacetic acid 
• 128360-00-9 (2S,4R)-Methyl 4-hydroxy-1-<<2-(trimethylsilyl)ethyl>oxycarbonyl>pyrrolidine-2-carboxylate 

Relevant articles and documents

MITOCHONDRIA-TARGETING PEPTIDES

Disclosed are non-natural peptides useful for the treatment and prevention of ischemia-reperfusion injury (e.g., cardiac ischemia-reperfusion injury) or myocardial infarction.

Studies on the synthesis of peptides containing dehydrovaline and dehydroisoleucine based on copper-mediated enamide formation

The preparation of peptide fragments containing dehydrovaline and dehydroisoleucine moieties present in the antibiotic myxovalargin is reported. Peptide formation is based on a copper-mediated C-N cross-coupling protocol between an acyl amide and a peptidic vinyl iodide. The presence of a neighboring arginine in the vinyl iodide posed a challenge with respect to the choice of the protecting group and the reaction conditions. It was found that ornithine - a suitable precursor - is better suited than arginine for achieving good yields for the C-N cross-coupling reaction. The optimized conditions were utilized for the synthesis of peptides 32, 33, 39 and 40 containing a neighboring ornithine as well as for the tripeptide 44 containing dehydroisoleucine with the correct stereochemistry.

NOVEL SEMI-SYNTHETIC GLYCOPEPTIDES AS ANTIBACTERIAL AGENTS

Semi-synthetic glycopeptides having antibacterial activity are described, in particular, the semi-synthetic glycopeptides described herein are made by chemical modification of the a glycopeptide (Compound A, Compound B, Compound H or Compound C) or the monosaccharide made by hydrolyzing the disaccharide moiety of the amino acid-4 of the parent glycopeptide in acidic medium to give the amino acid-4 monosaccharide; conversion of the monosaccharide to the amino-sugar derivative; acylation of the amino substituent on the amino acid-4 amino-substituted sugar moiety on these scaffolds with certain acyl groups; conversion of the amide group in amino acid-3 on these scaffolds to various acylamide, acylsulfonamide, acylsulfonylurea derivatives; aminomethylation with substituent containing sulfonamide or acylsulfonamide group on amino acid-7 through Mannich reaction; and conversion of the acid moiety on the macrocyclic ring of these scaffolds to certain substituted amides. Also provided are methods for the synthesis of the compounds, pharmaceutical compositions containing the compounds, and methods of use of the compounds for the treatment and/or prophylaxis of diseases, especially bacterial infections.

ANTIVIRAL PROTEASE INHIBITORS

The invention is related to compounds of Formula I or a pharmaceutically acceptable salt, solvate, ester, and /or phosphonate thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula (I) is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

HIV PROTEASE INHIBITING COMPOUNDS

A compound of the formula is disclosed as an HIV protease inhibitor. Methods and compositions for inhibiting an HIV infection are also disclosed.

Stabilized thyroxine compounds

Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism and depression. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine fr

Stabilized thyroxine compounds

Throxinyldimethylphosphinate was invented as a prodrug to stabilize thyroxine, a drug widely used to treat hypothyroidism. The presence of the dimethylphosphinate group at the phenolic hydroxyl of thyroxine is key to preventing thyroxine from decomposing

Synthesis and Evaluation of Novel Activated Mixed Carbonate Reagents for the Introduction of the 2-(Trimethylsilyl)ethoxycarbonyl(Teoc)-Protecting Group

The synthesis of 1-benzotriazole (Teoc-OBt) and 1-pyrrolidin-2,5-dione (Teoc-OSu) in high yields is reported.Both compounds are crystalline compounds that react with amino acids und